US Patent

US10265370 — Lisinopril formulations

Formulation · Assigned to Silvergate Pharmaceuticals Inc · Expires 2035-11-06 · 9y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable lisinopril oral liquid formulations for treating hypertension, heart failure, and acute myocardial infarction.

USPTO Abstract

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Drugs covered by this patent

Patent Metadata

Patent number
US10265370
Jurisdiction
US
Classification
Formulation
Expires
2035-11-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Silvergate Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.